McKesson Corporation was added to several Russell 1000 defensive-style indexes in late June 2026, while TempraMed announced an expanded North American distribution partnership with McKesson Medical-Surgical to broaden access to its temperature-controlled medication solutions. These developments highlight McKesson's role as a key healthcare distribution infrastructure provider and reinforce its positioning in indices focused on defensive characteristics. The index inclusions may modestly increase index-related flows but do not materially change near-term catalysts around specialty growth and efficiency gains, nor reduce structural risks from regulation, consolidation, and pricing pressure. The TempraMed partnership connects to McKesson's opportunity in higher value-added services and complex logistics, as broader access to temperature-controlled solutions fits with rising supply chain complexity benefiting large distributors. McKesson's narrative projects $499.3 billion revenue and $6.1 billion earnings by 2029, with a fair value estimate of $941.40 per share, representing a 25% upside to its current price.
McKesson CorporationAdded to Russell 1000 defensive-style indexes, likely driving index-related inflows.
Expanded North American distribution partnership with McKesson Medical-Surgical broadens market access for TempraMed's temperature-controlled medication solutions.